Curis, Inc. (CRIS)
NASDAQ: CRIS · Real-Time Price · USD
0.6775
-0.0591 (-8.02%)
Oct 8, 2026, 12:29 PM EDT - Market open
Curis Employees
As of December 31, 2025, Curis had 24 total employees, including 20 full-time and 4 part-time employees. The number of employees decreased by 10 or -29.41% compared to the previous year. That makes Curis the 37,674th largest employer in the world and 5,374th in the United States.
Employees
24
Change (1Y)
-10
Growth (1Y)
-29.41%
Revenue / Employee
$179,750
Profits / Employee
-$881,375
Market Cap
1.42M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | -10 | -29.41% | 20 | 4 |
| Dec 31, 2024 | 34 | -15 | -30.61% | 33 | 1 |
| Dec 31, 2023 | 49 | -2 | -3.92% | 49 | 0 |
| Dec 31, 2022 | 51 | -9 | -15.00% | 51 | 0 |
| Dec 31, 2021 | 60 | 32 | 114.29% | 60 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Virax Biolabs Group | 26 |
| Silexion Therapeutics | 14 |
| Decoy Therapeutics | 11 |
| Artelo Biosciences | 7 |
| CDT Equity | 4 |
| Silo Pharma | 3 |
| Bone Biologics | 2 |
CRIS News
- 7 weeks ago - Curis announces pricing of $5.6M public offering - TheFly
- 7 weeks ago - Curis Quarterly report: Q2 2026 - Filings
- 1 month ago - Curis, Inc. Announces Pricing of $5.6 Million Public Offering - PRNewsWire
- 1 month ago - Curis files to sell 3.73M shares of common stock, warrants - TheFly
- 1 month ago - Curis Registration statement: Registration filing - Filings
- 2 months ago - Curis doses first five patients in TakeAim CLL study - TheFly
- 2 months ago - Curis Doses First Five Patients in TakeAim CLL Study - PRNewsWire
- 2 months ago - Curis price target raised to $43 from $17 at H.C. Wainwright - TheFly